ASSET | DATE | % RETURN |
---|---|---|
SS Innovations International Inc Common Stock (SSII) | 4/13/2023 - 4/30/2023 | 120.63% |
Trevi Therapeutics (TRVI) | 4/13/2023 - 4/30/2023 | 87.98% |
Eyepoint Pharmaceuticals (EYPT) | 4/13/2023 - 4/30/2023 | 86.35% |
Tourmaline Bio (TRML) | 4/13/2023 - 4/30/2023 | 57.38% |
Edgewise Therapeutics (EWTX) | 4/13/2023 - 4/30/2023 | 51.99% |
Akebia Ther (AKBA) | 4/13/2023 - 4/30/2023 | 45.83% |
Sana Biotechnology (SANA) | 4/13/2023 - 4/30/2023 | 38.48% |
Akso Health Group ADR (AHG) | 4/13/2023 - 4/30/2023 | 38.2% |
Olema Pharmaceuticals (OLMA) | 4/13/2023 - 4/30/2023 | 35.31% |
Pulse Biosciences (PLSE) | 4/13/2023 - 4/30/2023 | 31.7% |
Oculis Holding AG Ordinary shares (OCS) | 4/13/2023 - 4/30/2023 | 30.94% |
American Coastal Insurance (ACIC) | 4/13/2023 - 4/30/2023 | 30.7% |
IperionX Limited American Depositary Share (IPX) | 4/13/2023 - 4/30/2023 | 30.45% |
LENZ Therapeutics (LENZ) | 4/13/2023 - 4/30/2023 | 29.68% |
Design Therapeutics (DSGN) | 4/13/2023 - 4/30/2023 | 29% |
Beazer Homes USA (BZH) | 4/13/2023 - 4/30/2023 | 28.92% |
Lindblad Expeditions (LIND) | 4/13/2023 - 4/30/2023 | 28.82% |
Idaho Strategic Resources (IDR) | 4/13/2023 - 4/30/2023 | 27.7% |
UroGen Pharma (URGN) | 4/13/2023 - 4/30/2023 | 27.5% |
Magnera Corp placeholder (MAGN) | 4/13/2023 - 4/30/2023 | 27.32% |
Mind Medicine (MNMD) | 4/13/2023 - 4/30/2023 | 26.91% |
Vasta Platform (VSTA) | 4/13/2023 - 4/30/2023 | 26.67% |
Forestar (FOR) | 4/13/2023 - 4/30/2023 | 25.99% |
WW International, Inc Common Stock (WW) | 4/13/2023 - 4/30/2023 | 25.94% |
PROG (PRG) | 4/13/2023 - 4/30/2023 | 25.02% |